How the literature manages it
The levers for anti-cancer drug nephrotoxicity — hold, dose-reduce, switch class, discontinue — plus corticosteroids and other immunosuppressants, eculizumab, glucarpidase, and when a kidney biopsy is worthwhile. Lesion-specific, because management follows the lesion, not the drug.
Educational use only. Educational synthesis of the published literature — not a treatment protocol, dosing guide, or medical advice. Regimens and agents shown are illustrative of what the literature describes; verify against current guidelines (ASON / KDIGO / ASCO / NCCN) and individualize to the patient. Using this site creates no clinician–patient relationship.
The escalation ladder
How severity (CTCAE-style grade) maps to action — the spine of every lesion below.
Mild (grade 1)
Usually continue with closer monitoring; correct reversible cofactors (volume, co-nephrotoxins, electrolytes).
Moderate (grade 2)
Hold the drug, work up the cause, and start lesion-specific therapy (e.g. corticosteroids for immune nephritis). Resume — often dose-reduced — only after recovery.
Severe (grade 3–4)
Hold/stop, treat aggressively, and for many immune or microvascular lesions permanently discontinue. Rechallenge only after careful, individualized risk–benefit assessment.
Hold
The universal first step for a significant, unexplained creatinine rise — buys time to diagnose.
Dose-reduce / delay
For lower-grade or recovered events where the agent remains valuable.
Switch within class
To a less nephrotoxic congener (e.g. cisplatin → carboplatin/nedaplatin). Note: it does not always avoid a class-level mechanism (e.g. another checkpoint inhibitor can still cause AIN).
Switch out of class
When re-exposure risk is unacceptable — especially drug-induced TMA, which tends to recur on rechallenge.
When to perform a kidney biopsy
A biopsy is most useful when it will change management. Common reasons it is considered:
- Diagnostic uncertainty — AKI without an obvious cause, or features that don't fit the expected lesion.
- Atypical findings — proteinuria, hematuria, or active sediment suggesting glomerular disease or TMA.
- To confirm immune interstitial nephritis and guide corticosteroid duration and the decision to rechallenge.
- Before committing a patient to prolonged immunosuppression.
Real-world caveat: biopsy is frequently deferred in cancer patients (thrombocytopenia, anticoagulation, a single functioning kidney, frailty), so immune interstitial nephritis is often treated empirically. The decision is individualized.
The pharmacologic toolkit
Corticosteroids
Immune interstitial nephritis (checkpoint inhibitors)
MMF / infliximab
Steroid-refractory immune nephritis
Eculizumab
Severe / refractory drug-induced TMA
Glucarpidase + leucovorin
High-dose methotrexate toxicity
RAAS blockade (ACEi/ARB)
VEGF-pathway proteinuria & hypertension
Electrolyte repletion
Cisplatin / anti-EGFR Mg–K wasting
Mesna + hydration
Oxazaphosphorine hemorrhagic cystitis
Rasburicase + hydration
Tumor-lysis urate crystal nephropathy
Tocilizumab
CAR-T / bispecific CRS prerenal AKI
By lesion
Each signature has its own approach — and its own answer to “when to biopsy.”
Acute Tubular Necrosis
Agents & detail →Prevention is the mainstay; once established, supportive care while the tubule recovers.
Drug-level levers
- Hold the agent for a significant creatinine rise; resume only after recovery.
- Dose-reduce or extend the dosing interval for lower-grade or recurrent injury.
- Switch within class to a less nephrotoxic platinum (carboplatin or nedaplatin) when a platinum must continue.
- Switch out of class to a non-nephrotoxic regimen if re-exposure risk is unacceptable.
Pharmacologic toolkit
- Volume expansion — Isotonic saline before and after dosing is the best-evidenced preventive measure for cisplatin ATN.
- Magnesium repletion — Replace urinary magnesium and potassium losses; magnesium supplementation may be renoprotective.
- Avoid co-nephrotoxins — Hold NSAIDs, aminoglycosides, and iodinated contrast where possible.
When to biopsy
Rarely needed — the diagnosis is usually clinical (timing, muddy-brown granular casts). Reserve biopsy for atypical features or when an alternative lesion (AIN, TMA) is suspected.
Monitoring
- · Creatinine / eGFR before each cycle
- · Serum magnesium and potassium
- · Urine output and sediment
Acute Interstitial Nephritis
Agents & detail →Per the ASON position statement: hold the drug, remove AIN cofactors, and treat with corticosteroids; biopsy when feasible to confirm and guide duration.
Drug-level levers
- Withhold the checkpoint inhibitor for grade ≥2 AKI.
- Discontinue concurrent AIN-culprit drugs (PPIs, NSAIDs, antibiotics).
- Permanently discontinue for grade 3–4 or recurrent immune-mediated nephritis.
- Rechallenge can be considered after recovery for lower-grade events — individualized, with close monitoring, given the recurrence risk.
Pharmacologic toolkit
- Corticosteroids — First line for grade ≥2: illustratively prednisone ~0.5–1 mg/kg/day (IV methylprednisolone for severe disease) with a slow taper over 4–6+ weeks.
- Steroid-refractory immunosuppression — For steroid-dependent or refractory AIN, agents such as mycophenolate mofetil or infliximab have been used.
When to biopsy
Favored when feasible to confirm AIN, exclude mimics, and guide steroid duration and rechallenge — but frequently deferred in cancer patients (thrombocytopenia, anticoagulation, single functioning kidney), so empiric corticosteroid treatment is common.
Monitoring
- · Creatinine before each cycle
- · Urinalysis (sterile pyuria, proteinuria)
- · Watch for concurrent immune-related adverse events
Thrombotic Microangiopathy
Agents & detail →Stop the culprit drug — the single most important step — with supportive care; complement inhibition for severe or refractory cases.
Drug-level levers
- Discontinue the offending agent promptly; re-exposure risk is high.
- Switch out of class for ongoing therapy — drug-induced TMA tends to recur on rechallenge.
- Control hypertension aggressively.
Pharmacologic toolkit
- Eculizumab (complement inhibition) — For severe or drug-discontinuation-refractory drug-induced TMA, eculizumab achieved renal recovery in ~80% of reported cases (gemcitabine, carfilzomib, bevacizumab).
- Supportive care — Transfusion, blood-pressure control, and dialysis as needed.
- Plasma exchange — Generally ineffective for drug-induced TMA (unlike TTP) and not routinely recommended.
When to biopsy
Consider when the diagnosis is unclear; but the peripheral smear (schistocytes), LDH, haptoglobin, and platelet count usually establish TMA noninvasively.
Monitoring
- · CBC, schistocytes, LDH, haptoglobin
- · Creatinine and blood pressure
- · Urine protein
Glomerular Injury / Proteinuria
Agents & detail →Reduce proteinuria with RAAS blockade and blood-pressure control; hold or dose-reduce for heavy or worsening protein leak.
Drug-level levers
- Hold for nephrotic-range proteinuria or a rapidly rising UPCR; resume at a reduced dose after improvement.
- Dose-reduce for moderate proteinuria.
- Switch out of class if proteinuria is severe or persistent.
Pharmacologic toolkit
- RAAS blockade — ACE inhibitor or ARB to lower proteinuria and treat coexisting hypertension.
- Blood-pressure control — Tight control limits further glomerular stress.
When to biopsy
Consider for nephrotic-range proteinuria, hematuria, or atypical features to define the glomerular lesion (e.g., collapsing FSGS, TMA) and inform whether to continue therapy.
Monitoring
- · Urine protein/creatinine ratio at baseline and periodically
- · Blood pressure
- · Creatinine / eGFR and albumin
Electrolyte Wasting
Agents & detail →Replace what is wasted; the drug usually continues.
Drug-level levers
- Therapy is typically continued with ongoing repletion.
- Dose-reduce or hold only for severe, symptomatic, or refractory derangements.
Pharmacologic toolkit
- Magnesium repletion — Oral and IV magnesium for anti-EGFR and cisplatin hypomagnesemia; losses are often substantial and recurrent.
- Potassium / calcium repletion — Correct coexisting hypokalemia and hypocalcemia (often magnesium-dependent).
When to biopsy
Not indicated — this is a functional tubular transport defect, not a structural lesion.
Monitoring
- · Serum magnesium, potassium, and calcium during and after therapy
Fanconi Syndrome
Agents & detail →Supportive electrolyte and acid–base repletion; often partially irreversible, so prevention (cumulative-dose limits) matters.
Drug-level levers
- Hold or avoid further exposure once Fanconi features appear.
- Respect cumulative-dose limits; use caution in young children and after prior cisplatin exposure.
Pharmacologic toolkit
- Electrolyte repletion — Phosphate, bicarbonate or citrate (for proximal renal tubular acidosis), and potassium replacement.
- Supportive — Monitor growth in children; some proximal tubular dysfunction persists long-term.
When to biopsy
Usually clinical (glucosuria with normal serum glucose, phosphaturia, proximal RTA); biopsy not routinely required.
Monitoring
- · Phosphate, bicarbonate, potassium, glucose
- · Growth in children
Crystal / Obstructive Nephropathy
Agents & detail →Prevent precipitation; for established high-dose methotrexate toxicity, glucarpidase rapidly cleaves circulating drug.
Drug-level levers
- Hold further methotrexate until clearance and renal recovery.
- For tumor-lysis urate nephropathy, prophylaxis is the key lever.
Pharmacologic toolkit
- Hydration + urinary alkalinization — Vigorous IV hydration and urine alkalinization keep methotrexate soluble.
- Leucovorin rescue — High-dose leucovorin guided by serial methotrexate levels.
- Glucarpidase — For delayed methotrexate clearance / AKI: recombinant carboxypeptidase-G2 cleaves plasma methotrexate, usually allowing recovery without dialysis.
- Rasburicase (tumor lysis) — For urate crystal nephropathy from tumor lysis, with hydration; also manage hyperphosphatemia.
When to biopsy
Not indicated — the diagnosis is clinical and biochemical (drug levels, uric acid, urine crystals).
Monitoring
- · Serial methotrexate levels, creatinine, urine pH
- · Uric acid, phosphate, potassium (tumor lysis)
Hypertension
Agents & detail →An on-target, expected effect — treat the blood pressure and usually continue the drug.
Drug-level levers
- Continue the agent if blood pressure is controlled (hypertension correlates with on-target activity).
- Hold for severe/refractory hypertension or a hypertensive emergency; resume once controlled.
- Dose-reduce for grade 3 hypertension not controlled on therapy.
Pharmacologic toolkit
- Antihypertensives — An ACE inhibitor/ARB (also helps any proteinuria) and/or a dihydropyridine calcium-channel blocker are common first choices; avoid non-dihydropyridine CCBs with CYP3A4-metabolized TKIs.
When to biopsy
Not indicated for isolated hypertension.
Monitoring
- · Home and clinic blood pressure, especially in the first cycles
- · Urine protein
Prerenal / Hemodynamic AKI
Agents & detail →Restore perfusion and treat the driver (cytokine release); the kidney itself is usually structurally intact.
Drug-level levers
- Supportive — the agent is not directly nephrotoxic; AKI tracks the systemic syndrome (cytokine release, capillary leak, volume loss).
- Hold the agent for severe systemic toxicity per cytokine-release-syndrome grading.
Pharmacologic toolkit
- Volume resuscitation — Judicious fluids for hypoperfusion, balanced against capillary-leak edema.
- Tocilizumab / CRS-directed therapy — For CAR-T or bispecific cytokine release syndrome, IL-6 blockade (tocilizumab) ± corticosteroids treats the driver of prerenal AKI.
- Tumor-lysis prophylaxis — Where a high tumor burden coexists.
When to biopsy
Not indicated — prerenal / hemodynamic AKI is established by context; reserve biopsy for AKI that fails to recover after resuscitation.
Monitoring
- · Creatinine, urine output, volume status
- · Cytokine-release-syndrome grade
SIADH / Hyponatremia
Agents & detail →Manage the hyponatremia (fluid restriction, careful correction); avoid over-hydration around dosing.
Drug-level levers
- Avoid the large hypotonic fluid loads historically given with cyclophosphamide.
- Adjust dose timing and hydration strategy.
Pharmacologic toolkit
- Fluid restriction — First line for euvolemic hyponatremia.
- Careful sodium correction — Correct slowly to avoid osmotic demyelination syndrome.
When to biopsy
Not indicated — a water-handling disorder, not structural injury.
Monitoring
- · Serum sodium around dosing
- · Fluid balance
Hemorrhagic Cystitis
Agents & detail →Prevent with mesna and hydration; this is an outflow (bladder) toxicity, not nephron injury.
Drug-level levers
- Hold further dosing for significant hemorrhagic cystitis.
- Co-administer mesna with ifosfamide and high-dose cyclophosphamide.
Pharmacologic toolkit
- Mesna — Binds acrolein in the urine; standard prophylaxis with the oxazaphosphorines.
- Hydration / bladder irrigation — Forced diuresis; continuous bladder irrigation for established hemorrhagic cystitis.
When to biopsy
Not a kidney-biopsy lesion; cystoscopy for severe or refractory bladder bleeding.
Monitoring
- · Urinalysis for hematuria
- · Symptoms of cystitis
Pseudo-AKI
Agents & detail →Recognize it — do NOT stop effective therapy for a transporter-mediated creatinine rise without a true fall in GFR.
Drug-level levers
- Continue therapy; the creatinine rise reflects blocked tubular secretion, not injury.
- Avoid unnecessary dose reduction or discontinuation.
Pharmacologic toolkit
- Confirm with cystatin C — A preserved cystatin C–based eGFR while the creatinine-based eGFR falls confirms pseudo-AKI.
- No specific therapy — None is required for the artifact itself; manage any true coexisting AKI on its own merits.
When to biopsy
Not indicated for an isolated creatinine rise with bland sediment and a preserved cystatin C–based GFR.
Monitoring
- · Cystatin C–based eGFR when creatinine rises
- · Urinalysis to exclude true injury
Renal Cysts
Agents & detail →Usually asymptomatic and dose/duration-related; monitor, rarely act.
Drug-level levers
- Continue therapy in most cases; the cysts often regress when the drug is stopped.
- Hold and reassess only for complex cysts with concerning features or complications.
Pharmacologic toolkit
- No specific therapy — Surveillance imaging; intervention only for symptomatic or complicated cysts.
When to biopsy
Not routine; image characterization (and urology input) for complex or enlarging cysts to exclude malignancy.
Monitoring
- · Surveillance imaging as clinically indicated
Chronic Interstitial Nephropathy
Agents & detail →Largely preventive — cumulative-dose limits; established chronic interstitial fibrosis is often irreversible.
Drug-level levers
- Respect cumulative-dose thresholds (e.g., the nitrosoureas) and monitor for the delayed, creeping creatinine.
- Hold or avoid further exposure once progressive CKD appears.
Pharmacologic toolkit
- Supportive CKD care — Blood-pressure and proteinuria control, avoid added nephrotoxins; no specific reversal therapy exists.
When to biopsy
Consider to confirm chronic interstitial nephropathy and exclude treatable alternatives when the cause of progressive CKD is unclear.
Monitoring
- · Long-term creatinine / eGFR (months to years)
- · Blood pressure and proteinuria
Educational use only. Educational synthesis of the published literature — not a treatment protocol, dosing guide, or medical advice. Regimens and agents shown are illustrative of what the literature describes; verify against current guidelines (ASON / KDIGO / ASCO / NCCN) and individualize to the patient. Using this site creates no clinician–patient relationship.